A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro
- 1 March 2006
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 147 (5) , 524-532
- https://doi.org/10.1038/sj.bjp.0706646
Abstract
The role of adenosine A3 receptor activation during ischaemia‐like conditions produced by oxygen and glucose deprivation (OGD) was evaluated with extracellular recordings from the CA1 region of rat hippocampal slices. In all, 7 min of OGD evoked tissue anoxic depolarisation (AD, peak at ∼7 min from OGD start, n=20) and were invariably followed by irreversible loss of electrically evoked field epsps (fepsps, n=42). The selective adenosine A3 antagonists 3‐propyl‐6‐ethyl‐5[(ethylthio)carbonyl]‐2‐phenyl‐4‐propyl‐3‐pyridinecarboxylate (MRS 1523, 1–100 nM, n=31), N‐[9‐chloro‐2‐(2‐furanyl)[1,2,4]‐triazolo[1,5‐c]quinazolin‐5‐yl]benzeneacetamide (MRS 1220, 100 nM, n=7), N‐(2‐methoxyphenyl)‐N′‐[2‐(3‐pyrindinyl)‐4‐quinazolinyl]‐urea, (VUF 5574, 100 nM, n=3) and 5‐[[(4‐pyridyl)amino]carbonyl]amino‐8‐methyl‐2‐(2‐furyl)‐pyrazolo[4,3‐e]1,2,4‐triazolo[1,5‐c]pyrimidine hydrochloride (1 nM, n=4), prevented the irreversible failure of neurotransmission induced by 7 min OGD (n=45) and the development of AD in 20 out of 22 monitored slices. When tested on OGD episodes of longer duration (8–10 min, n=18), 100 nM MRS 1523 prevented or delayed the appearance of AD and exerted a protective effect on neurotransmission for episodes of up to 9 min duration. In the absence of AD, the fepsp recovery was almost total, regardless of OGD episode duration. These findings support the notion that A3 receptor stimulation is deleterious during ischaemia and suggest that selective A3 receptor block may substantially increase the resistance of the CA1 hippocampal region to ischaemic damage. British Journal of Pharmacology (2006) 147, 524–532. doi:10.1038/sj.bjp.0706646Keywords
This publication has 47 references indexed in Scilit:
- ACTIONS OF ADENOSINE AT ITS RECEPTORS IN THE CNS: Insights from Knockouts and DrugsAnnual Review of Pharmacology and Toxicology, 2005
- Brief, repeated, oxygen‐glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: role of adenosine receptorsBritish Journal of Pharmacology, 2003
- Synthesis, Biological Properties, and Molecular Modeling Investigation of the First Potent, Selective, and Water-Soluble Human A3 Adenosine Receptor AntagonistJournal of Medicinal Chemistry, 2002
- Effect of γ-butyrobetaine on fatty liver in juvenile visceral steatosis miceJournal of Pharmacy and Pharmacology, 2001
- The ischaemic penumbraCurrent Opinion in Neurology, 2001
- Glutamate Does Not Mediate Acute Neuronal Damage after Spreading Depression Induced by O2/Glucose Deprivation in the Hippocampal SliceJournal of Cerebral Blood Flow & Metabolism, 2000
- Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slicesBritish Journal of Pharmacology, 1999
- Adenosine A3 Receptors Potentiate Hippocampal Calcium Current by a PKA-dependent/PKC-independent PathwayNeuropharmacology, 1997
- Derivatives of the Triazoloquinazoline Adenosine Antagonist (CGS15943) Are Selective for the Human A3Receptor SubtypeJournal of Medicinal Chemistry, 1996
- Investigations into the Adenosine Outflow from Hippocampal Slices Evoked by Ischemia‐Like ConditionsJournal of Neurochemistry, 1993